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3Abstract
Balkan endemic nephropathy (BEN) is a chronic tubulo-interstitial disease
with insidious onset, slowly progressing to end-stage renal disease and
frequently associated with urothelial carcinoma of the upper urinary tract
(UTUC). It was described in South-East Europe at Balkan peninsula in rural
areas around tributaries of the Danube River. After decades of intensive
investigations, the causative factor was identified as the environmental
phytotoxin aristolochic acid (AA) contained in Aristolochia clematitis,  a
common plant growing in the wheat fields, which was ingested through home-
baked bread. AA was initially involved in the outbreak of cases of rapidly
progressive renal fibrosis reported in Belgium after intake of root extracts of
Aristolochia fangchi imported from China. A high prevalence of UTUC was
found in these patients. The common molecular link between Balkan and
Belgian nephropathy cases was the detection of aristolactam-DNA adducts in
renal tissue and UTUC. These adducts are not only biomarkers of prior
exposure to AA but they also trigger urothelial malignancy by inducing
specific mutations (A:T to T:A transversion) in critical genes of carcinogenesis
including the tumour suppressor TP53. Such mutational signatures are found
in other cases worldwide, particularly in Taiwan, highlighting the general
public health issue of AA exposure by traditional phytotherapies.
Keywords:  Balkan endemic nephropathy, aristolochic acid nephropathy,
upper tract urothelial carcinoma, aristolochic acid, Aristolochia species
41. Introduction
In 1993, the occurrence of a rapidly progressive form of renal
interstitial fibrosis associated with a weight loss diet which included the
ingestion of pulverized plant extracts used in traditional Chinese medicine, led
to the description of a new toxic nephropathy.1 The identification of
aristolochic acid (AA) in these powders brought to attention the severe
toxicity of certain species of Aristolochia.2 Ever since, secondary
nephropathies resulting from the toxicity of plants containing AA have been
described worldwide.3 The similarity between the histological aspects of this
particular nephropathy and the so-called Balkan endemic nephropathy (BEN)
proved instrumental in reviving an old hypothesis on the etiology of BEN.1,4
In 1969, Ivic had suggested that the latter, occurring in certain villages
throughout the Danube Valley, might be caused by the chronic ingestion of the
seeds of the Aristolochia clematitis, a common plant growing in the wheat
fields of these endemic regions.5 This hypothesis has now been confirmed by
the discovery of specific DNA adducts that are formed by the metabolites of
AA (aristolactams) in the renal tissue and the urothelial tumours of those
patients suffering from BEN as well as in the initial cohort of Belgian
patients.6-9
Today, the term “aristolochic acid nephropathy” (AAN) is used to
include any form of toxic interstitial nephropathy that is caused either by the
ingestion of plants containing AA as part of traditional phytotherapies
(formerly known as “Chinese herbs nephropathy”), or by the environmental
5contaminants in food (BEN).10
Although the initial Belgian cohort only included over one hundred
patients, it is estimated that exposure to AA affects 100,000 people in the
Balkans (where the total number of patients with kidney disease amounts to
approximately 25,000), 8 million people in Taiwan and more than 100 million
in mainland China.3,11 Given the fact that the nephrotoxic effects of AA are
irreversible and that its carcinogenic effects may be very slow in manifesting
themselves after the patient’s initial exposure, AAN and associated cancers are
likely to become a major public health issue in the years to come.12
The Aristolochia sp. is a genus of herbaceous, perennial plants that
include more than 500 species. They are widespread in the warm regions of
the Mediterranean, Africa and Asia. In France, Aristolochia clematis or
birthwort, Aristolochia rotunda and Aristolochia pistolochia grow mainly in
limestone soil and can be found on roadsides, in coppices, vineyards and other
agricultural areas. Furthermore, Aristolochia clematitis is a parasitic plant that
grows alongside wheat in the local wheat fields in the warm and humid
regions of the Danube Valley.13
The accidental ingestion of these species of Aristolochia not only
explains the existence of BEN, but also clarifies incidents of severe livestock
poisoning, occurring among horses in the Balkans and goats in Africa,
respectively.5,14 In Spain, moreover, the regular consumption of an infusion
with Aristolochia pistolochia led to a case of chronic interstitial nephritis.15
In the past, Aristolochia were widely used in Western medicine.13 In
6fact their first use to stimulate the expulsion of the placenta during childbirth
was responsible for coining the name “Aristos lokos” or “excellent
delivery”.16 Since the plants were also recommended for treating snake bites,
Aristolochia were included in the preparation of Theriac. As a result, they
were prescribed for treating gout (Dutchman’s pipe).
Besides the dramatic history of AA environmental exposure in the
Balkans that will be further described in this review article, it should be
underlined that regarding global public health issues, Aristolochia are
considered an integral part of the herbology used in Traditional Chinese
Medicine (TCM),12 Japanese Kampo17 and Ayurvedic medicine.18 They are
found within the same therapeutic family as the Akebia, Asarum, Cocculus and
Stephania plants. Referred to by common names such as Mu Tong, Mokutsu
and Fang ji, they are used in a multitude of herbal mixtures for therapeutic
use.3 Due to the ambiguity surrounding the nomenclature of medicinal plants
used in traditional medicine, the detection of AA by means of the
phytochemical analysis of plant extracts is the only way to certify their
potential toxicity.
2.  Epidemiology and etiology of BEN
BEN is a chronic tubulo-interstitial nephropathy associated with
urothelial carcinoma of the upper urinary tract (UTUC).19,20 It was described
in South East Europe at Balkan peninsula in rural areas located in the values of
7great tributaries of the river Danube. The first cases were recognized in the
middle of 20th century. Disease was observed only in harvesting farmers
affecting certain villages. Family or more precisely household aggregation was
reported in all BEN countries (Bosnia and Herzegovina, Bulgaria, Croatia,
Romania and Serbia) (Figure 1A). Inherited pattern of the disease was ruled
out by the fact that BEN often affected several members of the same
household not necessarily blood related. At the WHO meeting which was held
in Dubrovnik, Croatia, in 1964 the disease was named endemic nephropathy.
Average prevalence of diseased subjects in the past years ranges between 2-
5%. However, the prevalence of farmers suspected to have BEN is much
higher and was reported to be 10-15%. There were no gender differences,
although slight insignificant female predominance was found (1:1.2).
Importantly, it was never reported in children indicating that long period of
exposure to the environmental agent is needed. In last decades, the age when
BEN patients start to receive dialysis was shifted to older ages, raising the
question whether the etiological agent is still present or active. This is in
concordance with the results obtained in Croatian field surveys conducted
between 2005 and 2015, where neither new BEN nor new UTUC patients
were detected in some previously established BEN villages.21 Similar trends
were observed in Serbia.22,23
Early hallmark of BEN is proximal tubule damage, which is manifested as
low-molecular-weight (tubular) proteinuria and enzymuria that are in line with
the pathological findings – good preservation of glomeruli and a gradient of
8tubular atrophy with severe interstitial fibrosis which decreases in severity
from outer-to-inner cortex -. Two target tissues were identified in BEN
patients: 1) proximal renal tubular cells, leading to the interstitial fibrosis and
eventually chronic renal failure, and 2) urothelial (transitional) cells, leading to
high prevalence of UTUC. Specific mortality of UTUC was reported to be 55
times higher in Croatian EN county vs. other parts of Croatia and similar
findings were found in Serbia and other countries where BEN was
observed.19,20,23,24 Epidemiological findings and striking geographical
correlation of two otherwise very rare diseases (chronic interstitial
nephropathy and UTUC) pointed to a common etiological agent. Čeović et al.
(1985) reported first firm evidence on the importance of environment and life
style observing that Ukrainians who settled the Croatian endemic villages and
lived in this area for more than 20 years had the same risk for BEN as local
autochthonous farmers.25 On the contrary, Ukrainians who settled at the same
time the Croatian non-endemic villages did not develop BEN, and finally,
BEN has never been described in Ukraine.
For more than 50 years extensive research has focused on the etiology
of BEN. Various hypotheses were investigated and rejected (heavy metals,
microelements, Pliocene lignite, bacteria, viruses, immunologic and metabolic
alterations, heredity and environmental toxins).19,20 In the critical evaluation of
environmental exposure agents suspected in the etiology of BEN, Voice et al.
(2006) concluded that mycotoxins and AA are the primary targets.26
Ochratoxin A (OTA) was mostly investigated but in 2006 the EU Committee
9on Food Safety reported that there was no convincing evidence from human
epidemiology to confirm the association between OTA exposure and the
prevalence of BEN or UTUC.27 This conclusion was based on several
important facts: 1) OTA is present in food worldwide; 2) significant overlap
was found in the average OTA contamination levels of relevant food
categories between BEN and non-BEN areas; 3) higher average blood OTA
concentration were reported in patients with different chronic kidney diseases,
thus accumulation of OTA is a consequence rather that the cause of impaired
renal function; 4) established tolerable weekly intake (TWI) of 120 ng/kg
body weight was significantly higher than the highest values ever reported in
BEN patients. In addition to inconclusive epidemiology, histopathology
differences and different type of cancer between BEN patients and OTA-
induced animal tumours were reported. Finally, there is no evidence of general
OTA toxicity in humans.16
The AA hypothesis was first launched in 1969 by Ivić, who observed
that the plant Aristolochia clematitis grew much more abundantly in Serbian
endemic than in non-endemic areas.5 Ivić realized that farmers unaware of
plants toxicity brought grain contaminated by Aristolochia seeds for grinding
into flour and concluded that the bread of those peasants was poisonous. He
conducted several in vitro experiments and proved that pathological findings
in rats fed with Aristolochia seeds completely corresponds to the changes
characteristic of BEN. Already ten years before, Martinčić and Dumić had
reported horse poisoning with Aristolochia clematitis and found strict
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similarities in epidemiology, clinic, laboratory data and renal pathology
between horses and BEN.28 Remarkably, over the next 35 years no attempt
was made to confirm or follow-up these prescient observations until the first
description of “Chinese herb Nephropathy” in Belgium1, which called
attention to similarities in the pathologic features of AAN diagnosed in
Belgium and BEN.1,4 In 2003, Croatian and US physicians and scientists
started collaboration aiming to test the hypothesis whether chronic, low-dose
dietary ingestion of AA, in conjunction with individual genetic susceptibility,
accounts for all epidemiological and clinical features of BEN. Firstly, Hranjec
et al. (2005) confirmed that seeds of Aristolochia clematitis co-mingled with
the wheat grain used by villagers in Croatian endemic regions to prepare
bread.29 BEN patients observed Aristolochia clematitis in their meadows and
farming fields, as well as Aristolochia seeds among harvested wheat 20 years
ago, significantly more frequently than other end-stage renal disease (ESRD)
patients undergoing dialysis (Figure 1B). Wheat cultivating, home-bread
baking and difference in observation of Aristolochia clematitis in farming
fields as a risk factor for UTUC was confirmed in larger groups of residents of
Croatian and Serbian villages.30 Arlt et al. (2002a) raised the question whether
aristolactam-DNA adducts might be present in BEN patients and prima facie
evidence of exposure to AA in BEN was published in 2007 when aristolactam-
DNA adducts were detected in renal cortex and urothelial cancer tissue in
several Croatian BEN patients.6,31 Furthermore, in a group of Croatian and
Bosnian BEN patients, mutation of A:T pairs of the tumor suppressor TP53
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gene accounted for 89% of all mutations, with the majority (78%) being A:T
to T:A transversions, i.e. AA mutational signature.31 Later, the presence of
aristolactam-DNA adducts and characteristic TP53 mutations were confirmed
in Serbian and Romanian BEN patients.7,8 Jelaković et al. (2012) found
aristolactam-DNA adducts in 95% of cases with A:T to T:A transversion
mutations, proving a clear association of biomarkers of exposure and
carcinogenic effect; furthermore, they chemically identified AA in DNA
adducts using LC-ESI/MS/MS3.7 After this final evidence that in genetically
susceptible individuals dietary exposure to AA is causally related to BEN and
UTUC, de Broe proposed that the terms “Chinese Herb Nephropathy“ and
BEN should be abandoned and the term “AAN“ had to be introduced to cover
both clinical conditions.10 Interestingly, it was also reported that exposure to
AA in Croatian, Bosnian and Romanian BEN patients was associated not only
with UTUC but also with renal cell carcinomas.32,33 In addition, using whole-
exome sequencing method proved that AA mutational signature is not
restricted to the TP53 gene but is genome-wide present in Croatian and
Bosnian BEN/UTUC patients.34 It was questioned whether in the past bread
consumption was the only route of AA ingestion in BEN patients. Although
reports from Romania suggested that herbal medicine also might be a risk
factor for AA exposure in BEN, Ivković et al. (2014) in a large cohort of more
than 2,500 Croatian farmers rejected this hypothesis that the use of herbs and
herbal teas was not associated with BEN.35,36 Gruia and Pavlović speculated
whether other plants (maize and cucumber) were capable of absorbing AA and
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thus being a secondary source of food poisoning.37,38 Chan et al. (2016), by the
use of high-performance liquid chromatography (HPLC) coupled with
fluorescence detection method, identified and quantitated AA in corn, wheat
grain, and soil samples collected from the endemic village Kutleš in Serbia.39
They hypothesized that AA present in edible parts of crops originating from
AA-contaminated soil could be one of the pathways by which AA could enter
the human food chain.
The next question was how to explain decreasing prevalence of BEN
and how could this fit the AA hypothesis knowing that Aristolochia clematitis
is still growing in wheat fields in BEN countries (Figure 1B). Croatian
physicians and agronomists analyzed harvesting and milling practices and
found that important improvements occurred in the 1970s: 1) large common
mills were built and used instead of small village mills; 2) combines became
popular with much smaller holes in sieving machines enabling better
separation of much bigger Aristolochia from the wheat seeds (Jelaković et al.
unpublished data). This could explain why the incidence of BEN is decreasing
despite Aristolochia clematitis still being present in farming fields. Jelaković
et al. (2015) proved this by analyzing another “natural experiment”
determining the prevalence of BEN and proximal tubule damage in the group
of Bosnian non-endemic immigrants who settled Croatian endemic and non-
endemic regions after agricultural improvements were done.30 In contrast to
Ukrainians 70 years ago, the immigrant status of Bosnian who settled endemic
villages was a protective predictor for proximal tubule damage. This
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observation was confirmed with a similar report from Serbia.40 Thus, the
presence of Aristolochia in farming fields is a risk factor but only if associated
with particular agricultural practices and life style. BEN prevalence will
decrease and finally disappear, but in next few years, due to past exposure,
new BEN patients will still start dialysis and even more importantly new
BEN/UTUC patients will be diagnosed.
The next intriguing question was why BEN should be restricted only to
small well defined areas in several South-East European countries, while
Aristolochia clematitis is more or less ubiquitous plant.41 Nikolić et al. (2006)
analyzed the prevalence and space distribution of UTUC in Serbian endemic
and non-endemic villages, and was the first who proposed that BEN cases also
could be found in villages which were not acknowledged as endemic villages,
so-called “sporadic BEN cases“.42 Recently, his hypothesis was confirmed in a
molecular-epidemiological study, where aristolactam-DNA adducts and
signature mutation were found in 10 Croatian and Bosnian farmers living in
non-endemic villages (Jelaković et al., unpublished data).
3. Clinical-pathological features of BEN
There are no diagnostic features which are pathognomonic of
BEN.4,43,44 The most dominant morphologic characteristic is extensive
hypocellular interstitial fibrosis associated with tubular atrophy involving
medullary rays, that decrease in intensity from outer medulla and the cortical
labyrinth to the inner cortex (Figure 1C). Chronic interstitial inflammatory
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cells mainly in medullary rays and/or outer medulla, usually less than that
might be expected in other renal diseases, were found in less than one-third of
cases.43 As disease progresses, glomerular and vascular lesions are associated
with periglomerular fibrosis ending with obsolescent (collapsing type)
glomeruli, occasional thrombotic microangiopathy-like lesions and focal
segmental sclerosis-like lesions. Vascular lesions include arteriolar hyalinosis,
intimal fibrous hyperplasia, occasional mucoid arterial intimal fibrosis and
multifocal thickening and splitting up of peritubular capillary basement
membranes. At end-stage, the kidneys are extremely small, symmetrically
contracted, weighing only 20–30 grams each with smooth outlines. This type
of interstitial fibrosis shares remarkable similarities with the type of renal
fibrosis initially described in the Belgian cohort of AAN patients, which was
also associated with a similar prevalence of UTUC.45 As similar interstitial
fibrosis has been reported following exposure to cadmium, lead, cyclosporine
A, ifosfamide, pamidronate, lithium, nitrosoureas and some herbal tea,
exposure to these agents, as well as consumption of non-steroidal
antiinflammatory drugs, should be ruled out. The other important feature is
frequent occurrence of UTUC (40–46% cases).
Major characteristics of BEN and AAN are shown in Table 1. BEN has
insidious onset and slowly progress to ESRD. There is no leading typical
symptom (fatigue, loss of appetite, nocturia, polyuria). In the early phases,
aseptic leukocyturia and very seldom urine cylinders can be detected and urine
specific gravidity is low. Low-molecular-weight (tubular) proteinuria and
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enzymuria could be found. It was reported that anemia was more severe for
the stage of chronic kidney disease (CKD), probably due to destruction of
peritubular cells that secrete erythropoietin. Another important feature is
initially normal blood pressure and development of arterial hypertension in
advanced phases of CKD, which is mostly related to tubular damage and salt-
wasting. Recently, very probably because of later onset and milder forms of
hypertension, lower arterial stiffness and slower vascular aging was reported
in Croatian and Bosnian BEN patients undergoing dialysis compared to other
ESRD patients.46 However, a recent report from Croatia showed that the
prevalence of hypertension in BEN villages does not differ from other rural
parts of Croatia, very probably reflecting changes in lifestyle (high salt
intake), obesity and more stress.47
Different clinical courses were reported and BEN patients could have
1) only chronic tubulo-interstitial nephropathy leading to ESRD; 2)
simultaneously present UTUC (either unilateral or bilateral) with renal
impairment and typical BEN histopathology; 3) initial deterioration of kidney
function followed by UTUC (either unilateral or bilateral) (Figure 1C).
According to analyzed case reports, different clinical courses do not seem to
be related to differences in exposure, but more likely to differences in
metabolic activation or detoxification of AA and/or DNA repair resulting from
different genetic polymorphisms.48
4. DNA adducts formed by AA as markers of exposure and early phase of
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UTUC
Over the past decade, AA has emerged as a causative factor for BEN and
based on molecular epidemiology studies AA has been shown to be
responsible for the development of BEN-associated UTUC.49 DNA adducts
can be used as biomarkers of exposure and as markers of cancer risk.50 The
detection of aristolactam-DNA adducts in renal tissue unequivocally
demonstrated AA exposure in BEN patients.6-8 DNA damage produced by
aristolactam-DNA adducts is one rare example directly linking environmental
exposure to cancer development (UTUC) in humans.9,51 Previous studies have
demonstrated the role of aristolactam-DNA adducts in AAN-associated
tumourigenesis.50,51 Subsequently, AA has been classified as carcinogenic to
humans (Group 1) by the International Agency for Research on Cancer
(IARC) acting by a genotoxic mechanism.
The plant extract AA is a mixture of structurally related
nitrophenanthrene carboxylic acids, with aristolochic acid I (8-methoxy-6-
nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid, AAI) and aristolochic
acid II (6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid, AAII) being
the major components.16 Both compounds are mutagenic and genotoxic 52 but
AAI is considered to be responsible for AA-mediated nephropathy. Although
AAI might directly cause interstitial nephropathy, enzymatic activation of AAI
is required to exert its genotoxic (i.e. DNA damaging) properties. Reduction of
the nitro group is considered the major activation pathway of AA. This
reaction is primarily catalyzed by cytosolic nitroreductases, such as
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NAD(P)H:quinone oxidoreductase (NQO1), and microsomal enzymes such as
NADPH:cytochrome P450 (CYP) oxidoreductase (POR) and CYPs,
predominantly CYP1A1 and CYP1A2.53 Another AA-activating enzyme is
cyclooxygenase (COX), which is highly expressed in urothelial tissue. Besides
activation, CYP enzymes can also be involved in the oxidative detoxification
of AAI through O-demethylation (i.e. the formation of 8-hydroxyaristolochic
acid I, also known as aristolochic acid Ia [AAIa]) resulting in a decrease in the
actual AAI concentrations that can lead to the attenuation of nephropathy
and/or (geno)toxicity. Differences in AA metabolism (activation versus
detoxification) might not only contribute to an individual’s susceptibility but
could also be an important determinant of cancer risk. Since not all individuals
exposed to AA suffer from BEN, besides differences in the cumulated dose of
AA and the duration of AA intake, differences in the activities of AA
metabolising enzymes may predispose certain residents in areas endemic for
BEN. However, studies evaluating genetic polymorphisms of AA-
metabolising enzymes have only resulted in controversial results [reviewed in
49] and thus this phenomenon remains to be further investigated.
The most abundant aristolactam-DNA adduct found in renal tissue of
BEN patients living in endemic regions in Croatia, Serbia, Bosnia and
Romania is 7-(deoxyadenosine-N6-yl)-aristolactam I (dA-AAI).6-8 This adduct
also shows a long persistence in renal tissue of AAN patients 9 and is still
detectable decades after AA exposure.50 Based on the structure of the
aristolactam-DNA adducts, it has been suggested that a cyclic N-acylnitrenium
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ion with a delocalised positive charge (aristolactam-nitrenium ion) is the
ultimate electrophilic species that binds preferentially to the exocycylic amino
groups of purine nucleotides in DNA through the C7 position of the
phenanthrene ring.51 For several decades, aristolactam-DNA adducts have
been analysed by the 32P-postlabeling assay; however, recent advances in
analytical chemistry have allowed use of mass spectrometry in both fresh and
formalin-fixed paraffin-embedded tissue for the identification of these
adducts, thus providing an alternative to the 32P-postlabeling technique.55
Aristolactam-DNA adducts (i.e. dA-AAI) are poorly removed by DNA
repair process (i.e. nucleotide excision repair) and thus can induce mutations,
predominantly characteristic A:T to T:A transversions, in cancer-related genes
including TP53. The same hotspot mutations were found in BEN and
Taiwanese AAN patients being located on the non-transcriptable DNA chain,
thus unrepairable.56 It is also noteworthy that in rodents characteristic A:T to
T:A transversion mutations have been observed in codon 61 of H-ras
highlighting the underlying mechanism of AA carcinogenesis in experimental
animals.57 Different environmental carcinogens like AA are known to cause
specific TP53 mutations and this is collectively referred to as TP53 mutation
signature.58 In addition to the determination of aristolactam-DNA adducts in
urothelial tissue of BEN patients, the TP53 mutation signature of AA in BEN-
associated tumors has been used as biomarker of effect in order to demonstrate
AA exposure in BEN patients.57,59 Indeed, a high prevalence of A:T to T:A
transversion mutations in TP53 has been found in urothelial tumors of BEN
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patients originating from Croatia, Serbia, Bosnia and Romania.59 This
mutation type is otherwise rare in urothelial tumors not associated with AA
exposure, thereby providing a molecular link between AA exposure and the
formation of BEN-associated UC across several geographical foci.49 Similar
TP53 mutation signatures have been observed in AAN-associated urothelial
tumors originating in other parts of the world (e.g. Taiwan).56 Further,
studying AA-induced TP53 mutagenesis using human TP53 knock-in (Hupki)
mouse embryo fibroblasts (HUFs) not only confirmed the TP53 mutation
signature of AA in HUFs immortalized after AAI exposure in vitro 58 but also
that AAI-treated HUFs share so-called hotspot TP53 mutations observed in
UTUC from BEN patients.59 These findings explain the molecular mechanism
whereby AA causes urothelial cancer.49  (Figure 2).
Massive next generation sequencing has allowed the analyses of
thousands of cancer genomes (exomes and whole genomes) across most
cancer types and this data is recorded in the Catalogue Of Somatic Mutations
In Cancer (COSMIC) database (http://cancer.sanger.ac.uk/cosmic). Currently
30 different base substitution mutational signatures have been published in the
COSMIC database in order to shed light on the etiology of human cancer.
Each base substitution signature is characterized by a 96-mutation
classification that includes the six substitution types together with the bases
immediately 5’ and 3’ to the mutated base. Some mutational signatures have
been linked to environmental exposures and this includes COSMIC Signature
22 which shows characteristic A:T to T:A transversion mutations and is
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attributed to AA exposure. One study conducted exome sequencing in 15 BEN
patients with UC and identified COSMIC Signature 22 confirming the
applicability of this approach to investigate the etiology of AA-induced
tumours.60 This study also identified a number of cancer driver genes: TP53,
AHNAK, ARID1B, ATRX, BLM, CHD2, CHD5, CHD8, CHD9, CHEK2,
CLTC, ERBB4, FN1, HUWE1, IARS2, KALRN, LRRK2, MLL2, NEB, RXRA,
SMCHD1, SPEG, STAG2, SYNE1 and TRIO. TP53 was the most frequently
mutated gene. Other recurrently mutated genes were related to regulation of
transcription, chromatin/histone modification, DNA damage response and
DNA repair.60
Using whole-genome sequencing exposure to AA in Romania was
recently implicated in the development of renal cell carcinoma (RCC).61 Again
COSMIC Signature 22 was identified in the Romanian cancer patients.
Subsequently, using mass spectrometry, the formation of aristolactam-DNA
adducts was confirmed in these patients unambiguously demonstrating
exposure to AA. RCC have not been reported in BEN patients but studies in
Asia (Taiwan) have linked AA exposure to this cancer type.62 The source of
AA exposure remains unclear in the Romanian cohort with RCC; however, it
is clear that these patients do not cover the Romanian population of the BEN
area.61 These results are in line with data obtained in Croatian study.32
5. Screening, diagnosing, classification and treatment of BEN
Until recently, different diagnostic criteria were used in different BEN
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centers. These criteria involved several combinations of parameters, various
cut-off values and many of them were not in agreement with proposed current
international guidelines. Therefore, leading experts developed consensus on
BEN criteria during the "International workshop on diagnostic criteria on
Endemic Nephropathy" held in Brač, Croatia in 2008. Despite extensive
research, no specific diagnostic biomarker for BEN has yet been identified.
Thus far, diagnosis of BEN is based on the combination of several clinical and
laboratory criteria.43 It was the hope of the authors of the Consensus document
that the use of these uniform criteria will make comparable obtained results of
conducted studies in different BEN countries, providing better insight in
understanding still unanswered questions of the disease and enabling to
provide better medical care for the population at risk.
Criteria for diagnosing BEN and classification of BEN village population
are summarized in Table 2.
Screening  The entire adult population of BEN villages should be screened by
mass screening every five years.43 This screening should include
determination of tubular proteinuria (α1-Microglobulin), estimated Glomerular
Filtration Rate (according to CKD-EPI equation), red blood cell count,
dipstick urinalysis and urine cytology. Those detected as "Diseased" should be
referred to local nephrologists. "BEN suspected" and members of BEN
households with no signs of either tubular proteinuria or UTUC should be
monitored yearly by the aforementioned “screening tool”. Patients with ESRD
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of unknown origin from non-endemic villages and members of their
households should be screened for sporadic BEN/UTUC.43 Patients at high
risk for developing UTUC (patients with histopathological findings indicative
of BEN, BEN patients in CKD stages ≥ 3A, BEN transplanted patients or
undergoing dialysis) should be monitored every 6 months, while their
household members yearly using urine cytology, ultrasound, and other
available imaging techniques if needed.43 Patients with previous UTUC,
bladder cancer or having hematuria should be examined every 3 months, and
those with hematuria should be evaluated by cystoscopy. If UTUC is highly
suspected, ureteropyeloscopy and CT scan should be performed as well. In all
UTUC patients from farming villages, renal cortex should be excised during
surgery (distant from tumor) and analyzed for evidence of BEN, and if
possible, should be frozen at -20°C for subsequent determination of the level
of aristolactam-DNA adducts and TP53 fingerprint mutation on tumor tissue.43
Treatment  Patients with established BEN should be treated like other CKD
patients, with peritoneal dialysis, hemodialysis or renal transplantation in
ESRD stage.43 BEN patients are at high risk of developing UTUC and should
undergo appropriate examinations to exclude urothelial cancers before being
placed on the waiting list for kidney transplantation. Thus, bilateral
nephroureterectomy should be performed in BEN patients prior to
transplantation. In case of living donor transplantation, it is important to
perform kidney biopsy of the donor(s) who lived in the BEN region for more
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than 15-20 years to exclude BEN and/or presence of AA-DNA adducts.43
Bilateral nephroureterectomy should be performed in all BEN recipients
younger than 65 years, and also in those older than 65 years if UUC or bladder
cancer has already been diagnosed or they have family history of UTUC.43
After transplantation, BEN patients who refused bilateral nephroureterectomy
should be monitor closely for urothelial cancer. Immunosuppression with
mTOR inhibitors should be considered for BEN-transplanted patients.
Regarding treatment of UTUC, total nephroureterectomy with excision of a
bladder cuff around ureteral ostium and regional lymphadenectomy is
standard therapy. A conservative surgical approach should be reserved only for
the highly selected patients with bilateral tumors.43 These patients have
increased risk of local recurrence and should be monitored closely. Systemic
chemotherapy is indicated for unresectable and metastatic disease if not
otherwise contraindicated.
In the Belgian cohort of AAN patients with ESRD, who were treated
with dialysis or kidney transplantation, a prophylactic bilateral
nephroureterectomy was also performed and bladder monitoring continued by
means of cystoscopies with randomized bladder biopsies at least every year.
Indeed, a significant amount of patients developed bladder cancer several
years after surgical removal of their native kidneys and ureters.63 In non-
invasive bladder cancer, treatment included endoscopic resections
supplemented by the endovesical instillation of mitomycin C. Endovesical
therapy based on the Bacillus Calmette-Guerin (BCG) was also successfully
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performed, even in patients with a renal graft, provided the therapy was
combined with modulation of immunosuppression and prophylactic anti-
tuberculosis chemotherapy.64 Radical cystectomy with pyelostomy of the graft
remains the ultimate measure in kidney transplant recipients with invasive
bladder cancer.
6. Nephrotoxicity assessment of AA by the “omics” approach
Innovative approaches used in System Biology, that encompasses
genomics, transcriptomics, proteomics and metabolomics, have gained great
interest in the last decades. Such techniques not only facilitate the
development of biomarkers and predictors, but they help gaining basic
biological insights into the disease etiology. Due to their multifactorial
character and the associated co-morbidities, an integrated approach can also be
helpful in redefining and stratifying chronic diseases. In the field of
nephrology, recent advances in omics technologies has created an opportunity
for integrating omics datasets to building a comprehensive and dynamic model
of the molecular changes in CKD.65 Several studies have already underlined
the advantage of using urine samples for non-invasive data collection
throughout disease progression. Moreover, it can also be adapted for patient
clustering, identification of diseased and at-risk populations in
epidemiological studies and, where appropriate, tailoring treatments to patients
via personalized medicine.66 On the other hand, in the context of risk
assessment of chemicals and natural substances, System Biology (also referred
in this case to toxicogenomics), enables the study of adverse effects of
25
xenobiotic substances in relation to structure and activity of the genome,
proteome and metabolome.67 Applied to nephrotoxicity, toxicogenomics
allowed for more sensitive and earlier detection of adverse effects in many in
vivo and in vitro preclinical toxicity studies, as reviewed by Zhao and Lin.68
An additional advantage is the possibility of studying the effects of exposure
to mixtures in more details. Using DrugMatrix, a large database including
gene expression data from rats exposed to diverse chemicals, a cluster of 30
genes was identified that could assess the nephrotoxic potential of a chemical
well before injury actually occurs.69
Recent advances in the development of omics-type biomarkers of
acute/chronic kidney diseases encouraged researchers to apply toxicogenomics
to AAN. From the plethora of genomic studies devoted to AAN, two major
findings emerge (detailed in section 4): i) aristolactam-DNA adducts, a direct
evidence of AA exposure, were identified in various animal and human studies
55 and ii) a specific AA-related mutational fingerprint mostly in oncogenes and
tumor suppressor genes was revealed in UTUC.70 From the proteomic side,
analyses of urinary, plasma and renal tissue resulted in differential expression
of several cytoskeletal, developmental and inflammatory kidney proteins in
AA-exposed and control mice.71 A proteomic signature of AA-exposure was
also identified in rat kidney and, interestingly, some of those proteins
presented obvious biological and medical significance.72 Finally, the
metabolomic approach also contributed to a better understanding of AAN both
in acute and chronic exposures. In fact, a wide range of metabonomic
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analytical techniques have been used lately in the modern research of TCM,
with a special focus on TCM toxicity issues. These techniques include proton
nuclear magnetic resonance (1H-NMR), gas chromatography-mass
spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-
MS). Using 1H-NMR analysis of urine samples, Duquesne et al compared the
severity of nephrotoxicity of AAI and AAII given alone or in combination to
rats.73 Main metabolic alterations, including increased urine levels of glucose,
amino acids and organic acids together with decreased concentrations in
hippurate were all together indicative of an acute proximal tubule injury.
These dose-dependent damages were confirmed by histology at later time
points and for longer period of exposure. Renal damage was more pronounced
with the mixture or AAII alone than AAI alone.
The metabolomic approach was also used for clinical and
epidemiological purposes. For instance, an NMR study conducted on
Romanian and Bulgarian BEN-diagnosed people treated by hemodialysis
highlighted the predictive advantage of metabolomics as compared to more
conventional criteria.74 NMR spectra of urine samples collected from Belgian
AAN women were actually compared to those collected from Croatian BEN
patients.75 Interestingly, both Belgian and Croatian patients presented close
urine metabolic profiles, bringing some new evidence that both diseases have
a common etiology. In the context of AAN, toxicogenomics has thus identified
DNA adducts in genes directly involved in the onset, promotion and
progression of urothelial cancer. Proteomics has undoubtedly advanced the
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discovery of novel biomarkers of this proximal tubular nephropathy. Many
hopes are now based on the predictive potential of these markers to quickly
point the evolution from acute to chronic nephrotoxicity. Finally,
metabolomics is certainly not left over. Based on a readily and non-invasively
accessible biological matrix, namely urine, this metabolic approach opens new
perspectives in patient stratification and follow-up, whether in terms of disease
progression or effectiveness of the therapeutic strategies provided.
7. Conclusion and perspectives
The combination of chronic interstitial nephropathy with UTUC tract
should suggest the diagnostic of AAN. In addition, a long-term residence in
endemic settlements of Balkan countries, but probably also in some other
countries where traditional harvesting was used till the middle of last century,
and an occupational history of farming should suggest the diagnostic of
environmental AAN, i.e. BEN.
Besides the consensus for diagnosing BEN described above, a general
consensus exists regarding the definition of diagnostic criteria for AAN.12 The
diagnosis of AAN can be considered as certain in any person who suffers from
renal  failure, in combination with any two of the following three criteria: a
renal histology displaying interstitial fibrosis with a cortico-medullary
gradient, a history of ingesting vegetal or herbal products whose
phytochemical analysis has demonstrated the presence of AA, and the
presence of aristolactam-DNA adducts (or the specific mutation A:T to T:A of
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gene TP53) in a kidney tissue sample or of a urothelial cancer. Nevertheless, if
only one of these three criteria can be demonstrated, the diagnosis of AAN
remains highly probable and examinations should be continued in this
direction. Whatever the case, the presence of either AA in plant extracts
ingested by patients or of aristolactam-DNA adducts in patients' renal tissue
samples, are central to a diagnosis that provides absolute certainty.
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Figure legends
Figure 1A. Balkan endemic nephropathy (BEN) areas in Croatia, Bosnia and
Herzegovina, Serbia, Romania and Bulgaria (in red).
Figure 1B. Aristolochia clematitis growing in the wheat fields and having
fruits in harvesting time (Croatian endemic area near the endemic village of
Kaniža, August 2013- photo by B. Jelaković) and seeds of Aristolochia
clematitis among wheat seeds (Serbian endemic village of Vreoci, August
2015- photo by J. Nikolić).
Figure 1C. 1C1: Macroscopic finding of a Croatian BEN patient from
endemic village of Kaniža (data on positive aristolactam-DNA adducts and
p53 signature mutation were published in ref 48: small kidney (length 7 cm,
weight 26 gram, smooth surface); Photomicrographs: 1C2: Gradual decrease
in fibrosis severity and tubular atrophy from outer-to-inner cortex (HEx40);
1C3: Interstital fibrosis and tubular atrophy with spared glomeruli (Hex 100);
1C4: Extensive interstitial fibrosis (Mallory x 100); 1C5: Macroscopic finding
of a Croatian patient with pyelon cancer from endemic village of Slavonski
Kobaš (data on positive aristolactam-DNA adducts and p53 signature mutation
were published in ref 31: kidney of normal length and weight with pyelon
cancer;  high grade transitional cell cancer (1C6:HEx100; 1C7 HEx400).
Courteously by Karla Tomić, MD, PhD pathologist in General Hospital
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Slavonski Brod.
Figure 2. Metabolic activation and DNA adduct formation by AA.
NQO1, NAD(P)H:quinone oxidoreductase; POR, NADPH:cytochrome
P450 oxidoreductase; COX, cyclooxygenase; CYP, cytochrome P450;
dG-AAI, 7-(deoxyguanosin-N2-yl)aristolactam I; dG-AAII, 7-
(deoxyguanosin-N2-yl)aristolactam II; dA-AAI, 7-(deoxyadenosin-N6-
yl)aristolactam I; dA-AAII, 7-(deoxyadenosin-N6-yl)aristolactam II;
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Table 1. Characteristics of BEN and iatrogenic AAN
BEN Iatrogenic AAN
Prevalence of affected
subjects in exposed
 population
2-5% 3-5%
Gender 1 No difference More women
Familial/household
aggregation
Yes No
Awareness of plant toxicity Unaware Inadvertent
Route of ingestion Home-baked bread Herbal remedies
Pathology Identical Identical
Incidence of UTUC 30-50% 44%
Clinical course 2 Insidious onset,
slow progression
Rapidly progressive
to ESRD,
Fanconi syndrome
1More women than men in AAN due to high number of Belgium women who
underwent slimming regime; 2Clinical course is dose-dependent i.e. in
Belgium and most of other AAN cases worldwide high dose of aristolochic
acid was ingested in shorter period. BEN = Balkan endemic nephropathy;
AAN = aristolochic acid nephropathy; UTUC= urothelial carcinoma of the
upper urinary tract.
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Table 2. Criteria for diagnosis and classification of BEN
Classification of BEN
I. Diseased/affected BEN cases II. Suspected BEN
(1) Biopsy proven/indicative of BEN1
or
(2) Residency in a BEN household
>20 years
+ tubular proteinuria2
+ decreased eGFR
+ anemia3
or
(3) Residency in BEN village >20
years
+ UTUC
+ tubular proteinuria2
(1) Residency in BEN household >20
years
+ reduced eGFR
+ anemia3
or
(2) Residency in BEN household >20
years
+ tubular proteinuria2
or
(3) Residency in BEN village >20
years
+ UTUC
III. High risk group for BEN IV. Sporadic BEN4
(1) Residency in BEN households >20
years
(2) Residency in households with
sporadic/suspected BEN cases >20
years
Biopsy proven/indicative of BEN in
patient with UTUC outside of the
endemic region or in member of their
household
1 There are no diagnostic features which are pathognomonic of BEN but the
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pattern of injury, in the absence of other disease is highly suggestive of this
entity. Detection of aristolactam-DNA adducts and TP53 fingerprint mutation
is diagnostic; 2 α1-Microglobulin >31.5 mg/g and α1-Microglobulin/ urine
albumin concentration  ratio ≥0.91; 3 Hemoglobin <120 g/L for men and
women >50 years, and <110 g/L for women ≥50 years; 4 Subjects with chronic
interstitial nephropathies where other causes should be excluded (reflux
nephropathy, chronic pyelonephritis, recurrent pyelonephritis, hypertensive
nephrosclerosis, exposure to lead, cadmium, cyclosporine A, ifosfamide,
pamidronate, lithium and nitrosoureas, heavy use of non-steroidal
antiinflammatory drugs.43
 47 
 

Figure 1A
 
Figure 1B.   
 
 48 
 
   
1C1.                                                      1C2.                                               1C3.                                                       1C4. 
  
1C5.                                                        1C6.                                                                         1C7. 
 
Figure 1C. 
 49 
 
Aristolochic acid I, II
(AAI, AAII)
Aristolactam I, II
nitrenium ion 
dA-AAI (persistant)
dA-AAII
dG-AAI
dG-AAII
+
5
4
8
7
6
9
O
O
NO 2
COOH
R
O
O
R
N
O
O
O
R
NH
O
N
H
N
HN
N
N
O
DNA
O
O
R
NH
O
N
H
NN
N
N DNA
Metabolic
activation
NQO1
POR
COX
CYP1A1/2
DNA adduct
formation
+DNA
Mutation
induction
A:T to T:A transversions
(in TP53 and other
cancer-related genes)
UTUC
 
Figure 2 
